Long-Acting Cabotegravir for HIV Prevention: Issues of Access, Cost, and Equity. Sharfstein JM, Killelea A, Dangerfield D. JAMA 2022 Feb 14. pii: 2789293. doi: 10.1001/jama.2022.0420.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sharfstein JM, Killelea A, Dangerfield D. Long-Acting Cabotegravir for HIV Prevention: Issues of Access, Cost, and Equity. JAMA 2022 Feb 14. pii: 2789293. doi: 10.1001/jama.2022.0420.
PMID: 35157006